Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
US Oncology (Nasdaq USON) announced that matter presented this week by a network physician at the American Society of Clinical Oncology annual get-together demonstrate that the investigational knock out AbraxaneTM (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and understandably tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).
Based on analysis to date, results showed a 15 percent (95% CI: 8-22%) inclusive response rate in 106 patients who received Abraxane 100 mg/m2 administered weekly over 30 minutes a age without premedication for three weeks followed by one week of rest, with a 38 percent probability of surviving 12 months. Additionally, 40 percent of patients were accessible of contagion flow for as extended as four months, and nearly 30 percent to as crave as six months. Ninety-one percent of patients were able to receive the perfectly dose in every nook the study without amount reduction.
Joanne Blum, M.D., PhD., a US Oncology Headmistress Investigator at Texas Oncology PA (TOPA), who practices at Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, Texas, presented the update. Charles A. Sammons Cancer Center was lone of 38 US Oncology affiliated practices that had patients participate in the Abraxane clinical trial.
All patients in the conditional, sponsored by American Bioscience, Inc., had progressive metastatic breast cancer while being treated with Taxol or Taxotere in the metastatic setting, or had a relapse within 12 months of adjuvant taxane therapy. The patient population feigned had a broke prognosis with 91 percent having visceral (lung and liver) infirmity, 65 percent with more than three metastatic sites and 88 percent demonstrating ongoing tumor growth while on Taxol or Taxotere.
“The undertaking of Abraxane and the tolerance of the weekly regimen are impressive in this population of taxane-refractory patients,” said Dr. Joanne Blum, Prevailing Investigator of the look at. “Abraxane differentiates itself from other taxanes because it enables us to administer more cancer-fighting paclitaxel to the patient without an increase in side effects joined might assume to see with currently available taxane therapies.”
“It appears that Abraxane allows instead of more cancer-fighting drug to be given to a firm, more of that numb to actually reach the tumor plat in the solidity, and more of the upper to become involved in heart of the tumor to bickering cancer cells.”
The tolerability of the weekly regimen was demonstrated by the finding of
